Home
Home
Product
Testing
Contact
Made with HTML Egg on a Mac
© Moletest (Scotland) Limited Reg No:SC47885
1 Exchange Crescent, Conference Square, Edinburgh EH3 8UL
Links
Product
Testing
Links
Contact
About Us
About Us
In 2013 we decided to configure our technology as a risk calculator for the medical profession. nomela® undertakes risk assessement of suspect skin lesions assigning them to either "No evidence of melanoma" or "Melanoma not excluded" groups. The purpose is to improve patient management and avoid unnecessary referrals to specialists. This makes nomela® a powerful tool to reduce demand on the health service. To undertake this new development Moletest Limited set up Moletest (Scotland) Limited which funded the Clinical Study conducted by NHS Lanarkshire. The Digital Health and Care Institute funded the statistical analysis of results which was undertaken by the University of Aberdeen.

Prior to the development of nomela®, Moletest Limited offered a completely different product, an online melanoma screening service for the UK public which was launched in 2010. This attempt to build an artificial intelligence system, using machine learning to distinguish between malignanct and non-malignant skin lesions failed for three reasons:
1/ The public were unwilling to risk an automated system informing them that they may have a life-threatening condition.
2/We underestimated the range of skin lesion conditions that might be mistaken as malignant and consequently the scope of the technical problem.
3/ There are insufficient numbers of example images with confirmed diagnoses for machine learning to work so the artificial intellence approach was not feasible. The lack of images arose from two factors:
- images of skin lesions are not routinely captured especially if they are deemed benign.
- there are complex ethical issues preventing use of such images unless the patient has explicitly provided signed consent for commercial use.

⬅️